Qube Research & Technologies (QRT)’s Regeneron Pharmaceuticals REGN Stock Holding History

Qube Research & Technologies (QRT)’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.62M	Sell	4,200 -2,800	-40%	-$1.91M	﹤0.01%	2009
2026 Q1	$5.41M	Sell	7,000 -17,700	-72%	-$13.6M	0.01%	1601
2025 Q4	$19.1M	Sell	24,700 -18,300	-43%	-$12.4M	0.02%	941
2025 Q3	$24.2M	Sell	43,000 -100	-0.2%	-$56.5K	0.03%	810
2025 Q2	$22.6M	Sell	43,100 -12,000	-22%	-$6.7M	0.02%	811
2025 Q1	$34.9M	Buy	55,100 +30,300	+122%	+$20.8M	0.04%	524
2024 Q4	$17.7M	Buy	24,800 +19,000	+328%	+$15.9M	0.02%	781
2024 Q3	$6.1M	Sell	5,800 -13,500	-70%	-$15M	0.01%	1290
2024 Q2	$20.3M	Sell	19,300 -76,000	-80%	-$73.7M	0.03%	602
2024 Q1	$91.7M	Buy	95,300 +90,700	+1,972%	+$86.2M	0.15%	174
2023 Q4	$4.04M	Sell	4,600 -12,700	-73%	-$10.5M	0.01%	1157
2023 Q3	$14.2M	Buy	+17,300	New	+$13.6M	0.04%	511

Other funds holding REGN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Qube Research & Technologies (QRT)'s REGN Position: Q2 2026 in Review

Qube Research & Technologies (QRT) increased its Regeneron Pharmaceuticals (REGN) stake by 166% in Q2 2026, buying an estimated $94.1M and bringing the position to 221,607 shares worth $138M. The position accounts for 0.13% of the portfolio, ranked #196.

Qube Research & Technologies (QRT) first reported a position in REGN in Q3 2018 and has held it in 23 quarters since. The position peaked at $446M in Q1 2025. 1,335 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

Qube Research & Technologies (QRT) held 221,607 shares of Regeneron Pharmaceuticals worth $138M as of Q2 2026.
Qube Research & Technologies (QRT) bought 138,249 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $94.1M.
Regeneron Pharmaceuticals made up 0.13% of Qube Research & Technologies (QRT)'s portfolio in Q2 2026, its #196 holding.
Qube Research & Technologies (QRT) first reported a position in Regeneron Pharmaceuticals in Q3 2018 and has held it in 23 quarters since.
Qube Research & Technologies (QRT)'s Regeneron Pharmaceuticals position peaked at $446M in Q1 2025.
1,335 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Qube Research & Technologies (QRT)'s 13F filing for Q2 2026, filed 14 Aug 2026.